A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMC-003 for Injection in Healthy Postmenopausal Women

this study is a randomized, double-blind, placebo-controlled, single and multiple dose escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IMC-003 for injection in healthy postmenopausal women.

NCT Number	NCT07118085
Lead Sponsor	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Conditions	Healthy Postmenopausal Women
Enrollment	56 participants
Start Date	2025-08-18
Primary Completion	2027-05-20 (estimated)
Study Completion	2027-08-20 (estimated)
Updated on ClinicalTrials.gov	2025-12-15